Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Carotid endarterectomy surgery

This article was originally published in The Gray Sheet

Executive Summary

Preliminary feedback from a trial of EndoTex's NextStent carotid stent with Boston Scientific's FilterWire EX embolic protection device is "promising," according to Boston Scientific Peripheral Interventions Business President Matthew Jenusaitis. CABERNET recently completed enrollment of 450 patients ineligible for carotid endarterectomy surgery at 15 U.S. centers, the firms announced March 25. Boston Scientific will be the exclusive distributor for NextStent and has the option to buy EndoTex under the terms of a May 2003 agreement extension (1"The Gray Sheet" May 26, 2003, p. 26)...

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts